Edition:
United States

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

160.23USD
4:00pm EDT
Change (% chg)

$-7.45 (-4.44%)
Prev Close
$167.68
Open
$167.96
Day's High
$168.05
Day's Low
$159.94
Volume
204,697
Avg. Vol
150,895
52-wk High
$217.85
52-wk Low
$89.90

ICPT.OQ

Chart for ICPT.OQ

About

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic... (more)

Overall

Beta: -2.23
Market Cap(Mil.): $4,146.12
Shares Outstanding(Mil.): 24.73
Dividend: --
Yield (%): --

Financials

  ICPT.OQ Industry Sector
P/E (TTM): -- 44.84 37.54
EPS (TTM): -14.04 -- --
ROI: -59.57 -0.27 13.98
ROE: -60.22 -2.93 14.88

Allergan to buy Tobira in push for fatty liver disease drugs

Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease closely linked to obesity.

Sep 20 2016

UPDATE 3-Allergan to buy Tobira in push for fatty liver disease drugs

Sept 20 Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease closely linked to obesity.

Sep 20 2016

BRIEF-Intercept Pharmaceuticals files new drug submission to Health Canada

* Intercept Pharmaceuticals files new drug submission to Health Canada for marketing approval of obeticholic acid for the treatment of patients with primary biliary cholangitis Source text for Eikon: Further company coverage:

Sep 19 2016

BRIEF-Intercept said on Sept 8, court granted final approval of previously announced agreement with lead plaintiff

* On Sept 8, court granted final approval of previously announced agreement with lead plaintiff to settle purported securities class action litigation

Sep 12 2016

BRIEF-Intercept Pharmaceuticals Q2 net loss per share $3.14

* Intercept pharmaceuticals reports second quarter 2016 financial results and provides business update

Aug 04 2016

BRIEF-Intercept Pharmaceuticals closes public offering of convertible senior notes

* Intercept Pharmaceuticals announces closing of public offering of convertible senior notes and exercise in full of option to purchase additional notes Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jul 06 2016

BRIEF-Intercept Pharmaceuticals announces pricing of public offering

* Intercept Pharmaceuticals announces pricing of public offering of convertible senior notes Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 30 2016

BRIEF-Intercept Pharmaceuticals files for convertible senior notes for up to $400 mln

* Files for convertible senior notes for up to $400 million - SEC filing Source text: (http://1.usa.gov/295S8vp) Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 29 2016

BRIEF-Intercept Pharmaceuticals announces public offering of convertible senior notes

* Says commenced an underwritten public offering of $400 million aggregate principal amount of convertible senior notes due 2023

Jun 29 2016

BRIEF-Intercept Pharmaceuticals appoints Sandip Kapadia as CFO

* Intercept Pharmaceuticals appoints Sandip Kapadia as chief financial officer

Jun 09 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.